Isolation, identification, and characterization of Candida species isolated from oral specimens of cancer patients and healthy individuals; a cohort study in Galle District, Sri Lanka Authors: Dharani Wanigasekara, Subodha Wickramasinghe, Gaya Wijayaratne, Mayuri Napagoda Published: 2025 ABSTRACT AbstractBackgroundThe incidences of opportunistic fungal infections have dramatically increased in recent years, causing significant mortality rates in hospitalized patients, where immunocompromised populations, such as cancer patients, are being the prime candidates. Candida species are considered the fourth most common cause of nosocomial infections. Over the years, these organisms have developed increased resistance to traditional antifungal agents owing to the widespread overuse of these drugs. This study focuses on the prevalence, antifungal resistance, and characterization of oral Candida colonization in two distinct populations: cancer patients and healthy community individuals.MethodsOral swabs and rinse samples were collected from 170 cancer patients who were admitted and visited the oncology unit of the National Hospital, Galle, Sri Lanka. The same number of healthy individuals was studied as the control group, and Candida isolation, identification, and characterization were carried out by standard microbiological methods. Morphological and physiological characteristics, species distribution, and antifungal susceptibility were investigated.ResultsA total of 220 yeast species were isolated, with 130 from the clinical group and 90 from the community group. Although C. albicans was the predominant oral colonizer in both cohorts, the identification results indicate different non-albicans Candida species profiles across them. Over 73% of the Candida albicans isolates were azole-resistant.ConclusionApart from Candida albicans, non-albicans Candida, such as Candida dubliniensis, Candida parapsilosis, Candida famata, Candida glabrata, Candida krusei, Candida rugosa, Candida pelliculosa, Candida guilliermondii, and Candida utilis were isolated from the oral cavities of cancer patients. Antifungal susceptibility data depict the emergence of azole resistance and amphotericin B resistance in the test population.Keywords: Antifungal resistance, Cancer patients, Non-albicans Candida, Oral Candida colonization Introduction Candida is a yeast species categorized under the kingdom Fungi and the class Ascomycetes [1]. Although 200 Candida species have been identified, most are harmless endosymbionts or commensals, and only 15 are human pathogens [2, 3]. Candida colonizes mucosal surfaces, skin, and the gastrointestinal tract of humans [4]. Infections caused by the opportunistic pathogen Candida have drawn more attention in recent years. The rise in HIV infection, immunosuppressive treatments, and the increased usage of antibiotics are responsible for the increasing significance of the infections caused by the opportunistic pathogen Candida. Immunosuppressed individuals are recurrently affected with severe fungal infections caused by opportunistic fungal pathogens. Among those opportunistic fungal species of human microbiota, Candida albicans is the predominant species. In addition to being a commensal, C. albicans is the most common opportunistic fungal pathogen, colonizing predominantly on the skin and mucosal surfaces [5]. C. albicans can remain without causing any symptoms as a commensal of humans. No environmental reservoirs are understood. It is usually transmitted congenitally to neonates and by nosocomial infection. Approximately 70% of healthy individuals carry at least one species of Candida commensally [6]. However, it can cause superficial and invasive candidiasis if the host’s immunity is impaired. Candidiasis is an umbrella term encompassing cutaneous, mucosal, and invasive infections caused by Candida species. Invasive candidiasis denotes bloodstream infections caused by Candida spp., also known as candidemia [7]. Invasive candidiasis is widely recognized as a major cause of morbidity and mortality in healthcare settings [7, 8]. Although 15 Candida spp. are recognized as human pathogens, the majority of invasive candidiasis is caused by six species: C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei, and C. auris. The latter has emerged as a major pathogen [2, 8–10]. Oral Candida colonization is prevalent among 20–60% of healthy individuals without showing specific symptoms [6, 7]. However, a transition from the harmless commensal state of Candida to a pathogenic form can occur due to alterations of the oral cavity environment that favor the overgrowth of Candida. These changes are known as the predisposing factors for candidiasis, and most often they are associated with weakened host immune defenses [11]. Oral candidiasis is among the most common oral infections in healthy individuals and immunocompromised patients, such as cancer patients. Oral candidiasis can exist in various forms, for instance, atrophic, erythematous, hyperplastic, osteomatosis, thrush, and angular cheilitis [8]. In immunocompromised patients, oral candidiasis may disseminate via the bloodstream or upper gastrointestinal tract, resulting in systemic candidiasis, which is associated with considerable morbidity and a mortality rate of 71%−79% [12]. Although Candida albicans is the predominant colonizer in the oral cavity of healthy individuals and immunocompromised patients, non-albicans Candida species also play a significant role in causing oral candidiasis. Several studies have depicted the contribution of non-albicans Candida species in oral carriage in AIDS, cancer, and critically ill patients [10, 13, 14]. However, no study has been published on the oral Candida colonization and characterization of oral Candida species of patients with malignancies in Sri Lanka. This study focused on investigating the occurrence of oral Candida species colonization in cancer patients and healthy individuals in Sri Lanka, identifying them up to the species level, and determining the antifungal susceptibility patterns. Materials and methods Study population In this study, 170 patients who attended the outpatient oncology clinics and were admitted to the oncology unit of the National Hospital, Galle, Sri Lanka, between December 2021 and March 2022 were recruited. The same number of healthy individuals residing in the Bope-Poddala MOH area in Galle district were recruited as controls. Consent declaration of the participants All the participants of the study were informed about the study and its procedures prior to sample collection, and written consent was obtained. Inclusion criteria Cancer patients and healthy adults older than 18 years who gave consent to participate in the study were recruited. Exclusion criteria Children younger than 18 years, terminally ill cancer patients, patients on antifungal therapy, and cancer patients and healthy individuals who did not give their consent for participation were excluded. Ethical approval The study protocol was approved by the Ethics Review Committee of the Faculty of Medicine, University of Ruhuna, Sri Lanka, under ERC Number 2019/P/059 on 27 November 2019. Sample collection and Candida isolation An oral rinse sample and an oral swab sample were obtained from each participant. The oral swab was directly inoculated on Candida Chrome Agar (CCA) (Himedia, India), and the rinse was centrifuged, followed by the decanting of the supernatant. The resultant pellet was collected and inoculated on CCA. The inoculated plates were incubated at 30 °C and 37 °C separately for 48 hours. Each yeast-like colony grown on CCA was purified by sub-culturing on Sabouraud Dextrose Agar (SDA) (HiMedia, India) and stored at 4°C. Each isolate was identified and characterized by colony characters on CCA, Gram staining, followed by microscopy, germ tube test, and bioMérieux API 20 C Aux system (bioMérieux, France). Gram-staining of isolates A drop of distilled water was placed on a clean microscope slide, and an adequate amount of the isolate was emulsified to prepare a thin smear. The smear was allowed to air dry, followed by heat fixing it by briefly passing it through the Bunsen flame. The smear was flooded with Ammonium Oxalate-Crystal Violet and left to stain for 30 seconds. Afterwards, Lugol’s iodine solution was added to the smear and allowed to sit for 30 seconds. Then the prepared slide was washed thoroughly with water. Then Iodine-Acetone solution was applied for 30 seconds to decolorize. Thereafter, it was washed thoroughly with water. Dilute Carbol fuchsin was applied for 30 seconds as a counterstain and was rinsed thoroughly with water, and the slide was blot-dried [15]. The whole smear was flooded with each reagent, and the previous reagent was completely washed at each stage. Care was taken not to waste stains by overflooding the slide with the stain. Finally, the slide was observed by the microscope, and cell shape, cell arrangement, and color were reported. Germ-tube test The germ tube test is a widely recognized and essential diagnostic procedure used to differentiate Candida species, particularly Candida albicans, from non-albicans Candida species. This test is based on the ability of certain Candida species to produce germ tubes, which are short, thread-like projections that emerge from the yeast cells [16]. To perform the germ tube test, a loopful of each overnight Candida culture is inoculated into an aliquot of human serum and incubated at 37 °C for 3 hours. A wet mount of the inoculum was observed through the high power of the microscope. The presence of germ tubes is a rapid and reliable way to presumptively identify C. albicans, as most other Candida species do not exhibit this characteristic [17]. bioMérieux API 20 C Aux yeast identification system The bioMérieux API 20 C Aux yeast identification system is a standardized tool used to identify yeast species, including Candida. This test strip consists of 20 wells, each containing a specific substrate for the detection of the metabolic activity of yeast species. Yeast suspension was prepared by picking a few colonies of the yeast from a fresh culture plate and suspending them in 5 mL of sterile saline solution to match the turbidity of a 2.0 McFarland standard (approximately 6x10⁸ CFU/mL). The prepared suspension was homogenized by gently mixing it. All the wells of the API 20 C Aux strip were inoculated with the prepared yeast suspension as per the manufacturer’s instructions to avoid overflow. The inoculated strip was covered with the given lid to prevent contamination and drying. The strip was incubated at 30°for 24–48 hours. Observations were made for turbidity changes as turbid wells were considered positive and vice versa. A numerical code for positive and negative wells was generated according to the user’s manual. Using the pattern of positive and negative reactions across the 20 wells, the identification software was used to identify the yeast species. The identification is based on a unique biochemical profile, with each species showing a specific combination of positive and negative reactions in the various wells. Antifungal susceptibility testing Disc diffusion method To determine the antifungal susceptibility of Candida isolates, the disc of each antifungal drug, including fluconazole (25 µg), amphotericin B (20µg) (Thermo Scientific TM Oxoid TM, England), and voriconazole (1 µg) (Liofilchem Diagnostics, Italy), was dispensed onto the uniformly inoculated plates with 24-hour-old (turbidity McFarland 0.5) Candida cultures, containing Mueller-Hinton agar (HiMedia, India), and incubated at 37 °C for 24 hours [18]. The susceptibility of Candida spp. was interpreted based on the CLSI zone interpretative criteria. Results Prevalence of Candida colonization in the oral cavity The study provided interesting insights into the prevalence of oral colonization of Candida and Candida-like yeasts among cancer patients and healthy controls. Among the 170 cancer patients, 103 (60.59%) had Candida in their oral cavities, whereas 76 (44.71%) of the 170 healthy controls carried Candida, indicating a higher prevalence among the patient group. Similarly, the number of Candida isolates isolated from the two groups was higher among the cancer patients, with 130 isolates (76.47%) compared to 90 isolates (52.94%) from the control group. These differences were statistically significant, with a p-value of 0.0032, suggesting that cancer patients have oral Candida colonization. In the cancer patient group (n = 170), 49 were male and 121 were female, of whom 31 (63.3%) males and 72 (59.5%) females exhibited oral Candida colonization. With respect to age distribution, no patients were recorded in the 18–25-year category, while three patients were between 26–35 years, including two with oral Candida carriage. Among the remaining groups, 36 patients were aged 36–45 years, with 20 (55.6%) carriers; 42 patients were 46 - 55 years, with 25 (59.5%) carriers; 46 patients were 56–65 years, with 25 (54.3%) carriers; 32 patients were 66–75 years, with 24 (75.0%) carriers; and 11 patients were 76–85 years, with seven (63.6%) oral Candida carriers. In the control group (n = 170), 57 were male and 113 were female, and oral Candida colonization was observed in 31 (54.4%) males and 72 (63.7%) females. The age distribution of the control group was comparable to that of the patient group, with no individuals in the 18–25-year category, and three individuals in the 26–35-year age category, of whom two were carriers. Among the older groups, 36 individuals were 36–45 years (20, 55.6% carriers), 42 were 46–55 years (25, 59.5% carriers), 46 were 56–65 years (25, 54.3% carriers), 32 were 66–75 years (24, 75.0% carriers), and 11 were 76–85 years (7, 63.6% carriers). The morphology of different Candida species is given in Fig. 1. a Candida albicans, (b) Candida rugosa, (c) C. dubliniensis on CCA medium (based on bioMérieux API 20 C Aux yeast identification) Gram-staining of isolates Although they exhibited different cell shapes and arrangements, all 220 isolates were gram-positively stained. A total of 90 round-shaped yeasts, 20 oval-shaped isolates, 18 elongated cells, and 02 irregularly shaped isolates were the cell shape distribution of all 130 isolates obtained from the cancer patients. Among 90 isolates from the control group, 59 isolates were round, whereas 22 isolates had an elongated cell shape, and 09 had an oval-shaped appearance, respectively. Distinct cell shapes of isolated Candida species are given in Fig. 2. a round yeast cells (b) elongated yeast cells The obtained colony morphologies of the Candida isolates are mentioned in the Table 1. Table 1Colony color of the isolates on Candida chrome agarYeast Species*Expected colony color#Colony color on Candida Chrome AgarBluish-greenBluePinkPurpleWhiteBeigeGray C. albicans Light green6230NilNilNilNilNil C. dubliniensis Not given85NilNilNilNilNil C. famata Not givenNil2573NilNil C. glabrata Cream to whiteNil217NilNilNilNil C. guilliermondii Not givenNil1Nil7NilNilNil C. krusei PurpleNilNil173NilNilNil C. parapsilosis Pale pinkNilNil51415NilNil C. pelliculosa Not givenNilNil11NilNilNil C. rugosa Not givenNilNil13NilNilNil C. tropicalis BlueNil2Nil1NilNilNil C. utilis Not givenNil1NilNilNilNilNil S. cerevisiae Not givenNilNilNil1NilNilNil Not valid NANilNilNil4Nil11*Species names based on API AUX 20 C identification#colony color according to the technical data sheet issued by the manufacturer Colony color of the isolates on Candida chrome agar *Species names based on API AUX 20 C identification #colony color according to the technical data sheet issued by the manufacturer Germ tube formation The isolates obtained from cancer patients had 60 germ-tube-positive isolates, whereas the control group had 37 germ-tube-positive isolates. The germ-tube-negative isolate numbers were 70 and 53, respectively. Germ tube test results of the isolates are given in Table 2. See Fig. 3 for the positive and negative germ tube test results. Table 2Germ tube formation by the isolatesSpecies*Number of isolatesGerm tube positiveGerm tube negativePatientCommunityPatientCommunityC. albicans57 (90.48%)27 (93.10%)6 (9.52%)2 (6.90%)C. dubliniensis3 (100%)10 (100%)0 (0.00%)0 (0.00%)Other non- albicans Candida species0 (0.00%)0 (0.00%)0 (0.00%)0 (0.00%)*Species names based on API AUX 20 C identification Germ tube formation by the isolates *Species names based on API AUX 20 C identification a Germ tube positive of C. albicans (b) Germ tube negative C. albicans API 20 C AUX identification BioMérieux API 20 C identification results of isolates of both the test and control groups are shown in the following table (Table 3). Table 3Identification results of 220 yeast-like isolates using the API 20 C AUX systemSpecies*Number of isolatesPatientCommunity(N%)(N%)C. albicans63 (48.46)29 (32.22)C. dubliniensis3 (2.31)10 (11.11)C. famata8 (6.15)9 (10.00)C. glabrata14 (10.77)5 (5.56)C. guilliermondii3 (2.31)5 (5.56)C. krusei11 (8.46)9 (10.00)C. parapsilosis19 (14.62)15 (16.67)C. rugosa1 (0.77)3 (3.33)C. tropicalis1 (0.77)2 (2.22)C. pelliculosa2 (1.54)0 (0.00)C. utilis1 (0.77)0 (0.00)Saccharomyces cerevisiae1 (0.77)0 (0.00)Not valid3 (2.31)3 (3.33)*Species names based on API AUX 20 C identification Identification results of 220 yeast-like isolates using the API 20 C AUX system *Species names based on API AUX 20 C identification Antifungal sensitivity of patient isolates All the isolates of C. glabrata, C. rugosa, and C. utilis were sensitive to amphotericin B and voriconazole; however, all C. glabrata isolates (100%) were resistant to fluconazole, indicating intrinsic resistance to this azole. Similarly, 100% of C. rugosa and C. utilis isolates were sensitive to all three antifungal agents tested. Antifungal susceptibility data of the Candida species isolated from the patients are depicted in Table 4. Table 4Antifungal susceptibility of Candida species isolated from cancer patientsSpecies*Total number of isolatesNumber and percentage of isolates N (%)FluconazoleVoriconazoleAmphotericin BResistantIntermediately sensitiveSensitiveResistantIntermediately sensitiveSensitiveResistantIntermediately sensitiveSensitiveC. albicans6350 (80.00)0 (0.00)13 (20.00)50 (80.00)0 (0.00)13 (20.00)17 (26.37)13 (20.00)33 (53.33)C. dubliniensis32 (66.67)0 (0.00)1 (33.33)2 (66.67)0 (0.00)1 (33.33)0 (00.00)1 (33.00)2 (67.00)C. glabrata1414 (100)0 (0.00)0 (0.00)14 (100)0 (0.00)0 (0.00)0 (0.00)0 (0.00)14 (100)C. guilliermondii32 (66.67)0 (0.00)1 (33.33)2 (66.67)0 (0.00)1 (33.33)0 (0.00)0 (0.00)3 (100)C. krusei1111 (100)0 (0.00)0 (0.00%)0 (0.00)0 (0.00)11 (100)0 (0.00)0 (0.00)11 (100)C. parapsilosis192 (11.11)0 (0.00)17 (88.89)2 (11.11)0 (0.00)17 (88.89)1 (5.56)2 (11.11)16 (83.33)C. pelliculosa21 (50.00)0 (0.00)1 (50.00)1 (50.00)0 (0.00)1 (50.00)0 (0.00)0 (0.00)2 (100)C. rugosa10 (0.00)0 (0.00)1 (100)0 (0.00)0 (0.00)1 (100)0 (0.00)0 (0.00)1 (100)C. utilis10 (0.00)0 (0.00)1 (100)0 (0.00)0 (0.00)1 (100)0 (0.00)0 (0.00)1 (100)C. famata83 (37.50)0 (0.00)5 (62.5)3 (37.50)0 (0.00)5 (62.50)2 (25.00)1 (13.00)5 (62.50)C. tropicalis11 (100)0 (0.00)0 (0.00)1 (100)0 (0.00)0 (0.00)0 (0.00)0 (0.00)1(100)*Species names based on API AUX 20 C identification Antifungal susceptibility of Candida species isolated from cancer patients *Species names based on API AUX 20 C identification All C. guilliermondii and C. pelliculosa isolates were sensitive to amphotericin B. However, resistance to azoles was observed in both species. Specifically, 66.67% of C. guilliermondii isolates were resistant to fluconazole and voriconazole, while only 33.33% were sensitive. In C. pelliculosa, 50% of isolates were resistant to fluconazole and voriconazole, and the remaining 50% were sensitive. Azole resistance was notably higher among C. albicans isolates: 80% were resistant to fluconazole, and only 20% were sensitive. With voriconazole, 26.37% of C. albicans isolates were resistant, 20.00% were intermediately sensitive, and 53.33% were sensitive. In contrast, a greater proportion (52.38%) of C. albicans isolates were sensitive to amphotericin B, while 26.98% were resistant and 20.63% intermediately sensitive. The antifungal resistance pattern of C. dubliniensis was similar to that of C. albicans.Two-thirds (66.67%) of C. dubliniensis isolates were resistant to fluconazole, and 33.33% were sensitive. All C. dubliniensis isolates were sensitive to voriconazole, except for one isolate (33.33%) that was intermediately sensitive. Regarding amphotericin B, 66.67% were sensitive, and 33.33% were intermediately sensitive, indicating that none were resistant. C. parapsilosis showed high susceptibility to all antifungal agents tested. Specifically, 88.89% of the isolates were sensitive to both fluconazole and voriconazole, while 11.11% were resistant to each. Regarding amphotericin B, 83.33% were sensitive, 10.53% were intermediately sensitive, and only 5.26% were resistant. Among C. famata isolates, 62.50% were sensitive to all three antifungal agents. 37.50% showed resistance to both fluconazole and voriconazole, while 25.00% were resistant to amphotericin B and 12.50% were intermediately sensitive to it. Antifungal sensitivity of community isolates Among Candida species isolated from healthy individuals, C. rugosa showed 100% sensitivity to all three antifungal agents: fluconazole, voriconazole, and amphotericin B. In contrast, C. krusei exhibited intrinsic resistance to fluconazole, with 100% of isolates resistant, though all were sensitive to voriconazole and amphotericin B. All C. glabrata isolates were resistant to both fluconazole and voriconazole but remained fully sensitive to amphotericin B. Antifungal susceptibility data of the Candida species isolated from healthy individuals are depicted in Table 5. Table 5Antifungal susceptibility of Candida species isolated from healthy individualsSpecies*Total number of isolatesNumber and percentage of isolates N (%)FluconazoleVoriconazoleAmphotericin BResistantIntermediately sensitiveSensitiveResistantIntermediately sensitiveSensitiveResistantIntermediately sensitiveSensitiveC. albicans2918 (62.50)0 (0.00)11 (37.50)18 (62.50)0 (0.00)11 (37.50)1 (4.00)6 (21.00)21 (75.00)C. dubliniensis107 (70.00)0 (0.00)3 (30.00)7 (70.00)0 (0.00)3 (30.00)0 (0.00)1 (10.00)9 (90.00)C. glabrata55 (100)0 (0.00)0 (0.00)5 (100)0 (0.00)0 (0.00)0 (0.00)0 (0.00)5 (100)C. guilliermondii51 (20.00)0 (0.00)4 (80.00)1 (20.00)0 (0.00)4 (80.00)0(0.00)0 (0.00)5 (100)C. krusei99 (100)0 (0.00)0 (0.00)0 (0.00)0 (0.00)9 (100)0 (0.00)0 (0.00)9 (100)C. parapsilosis152 (14.29)0 (0.00)13 (85.71)1 (7.14)0 (0.00)14 (92.86)0 (0.00)7 (46.67)8 (53.33)C. rugosa30 (0.00)0 (0.00)3 (100)0 (0.00)0 (0.00)3 (100)0 (0.00)0 (0.00)3 (100)C. famata91 (11.11)1 (11.11)7 (77.78)1 (11.11)0 (0.00)8 (88.89)1 (11.11)0 (0.00)8 (88.89)C. tropicalis21 (50.00)0 (0.00)1 (50.00)2 (100)0 (0.00)0 (00.00)0 (0.00)1 (50.00)1 (50.00)*Species names based on API AUX 20 C identification Antifungal susceptibility of Candida species isolated from healthy individuals *Species names based on API AUX 20 C identification C. tropicalis demonstrated complete resistance to voriconazole (100%), while 50% of the isolates were resistant to both fluconazole and amphotericin B. The remaining half were sensitive to these agents, indicating a concerning level of multidrug resistance. High levels of azole resistance were observed in C. albicans and C. dubliniensis. Among C. albicans isolates, 62.5% were resistant to both fluconazole and voriconazole, and 37.5% were sensitive. For C. dubliniensis, 70% of isolates were resistant to both azoles, and 30% were sensitive. Amphotericin B remained largely effective: 75% of C. albicans and 90% of C. dubliniensis isolates were sensitive, while intermediate susceptibility was reported in 21% and 10% of the isolates, respectively. Only a small proportion (4%) of C. albicans isolates were resistant to amphotericin B. In C. famata, resistance to fluconazole and voriconazole was observed in 11.11% of isolates, while 77.78% and 88.89% were sensitive to fluconazole and voriconazole, respectively. Amphotericin B sensitivity was noted in 88.89% of isolates, with 11.11% being resistant. C. guilliermondii isolates showed 80% sensitivity and 20% resistance to both azoles, while all were sensitive to amphotericin B. Among C. parapsilosis isolates, 85.71% and 92.86% were sensitive to fluconazole and voriconazole, respectively, with minimal resistance observed. Amphotericin B susceptibility was lower in this species, with 53.33% sensitivity and 46.67% intermediate susceptibility, though no resistance was detected. Refer to Fig. 4 for the antifungal susceptibility of C. albicans and C. parapsilosis. a a C. parapsilosis isolate sensitive to all three antifungals (b) an azole-resistant C. albicans isolate Table 6 illustrates the overall antifungal resistance of the isolates. Table 6Overall resistance of Candida isolates to the selected antifungalsCandida species*Fluconazole (%)Voriconazole (%)Amphotericin B (%) C. albicans 74.4837.764.57 C. dubliniensis 69.2367.690.00 C. famata 23.5317.6517.65 C. glabrata 100.000.000.00 C. guilliermondii 37.5037.500.00 C. krusei 100.000.000.00 C. parapsilosis 12.516.263.11 C. rugosa 0.000.000.00 C. tropicalis 66.6766.670.00 C. pelliculosa 50.0050.000.00 C. utilis 0.000.000.00*Species names based on API AUX 20 C identification Overall resistance of Candida isolates to the selected antifungals *Species names based on API AUX 20 C identification Discussion The recent emergence of antifungal-resistant fungal pathogens, such as Candida,has become a significant clinical concern worldwide. Chronic and prophylactic use of conventional antifungal agents may contribute to the acquisition of resistance. Cancer patients, on the other hand, are susceptible to opportunistic fungal infections such as candidiasis due to impaired immunity. Rapid and accurate identification of fungal pathogens is crucial for initiating appropriate therapy. Moreover, the misidentification of pathogenic yeast species may lead to the prescription of inappropriate treatment by physicians because many yeast species respond differently to azole and polyene antifungals [19, 20]. In addition, most of the clinical laboratories do not couple antifungal susceptibility testing with identification [21]. This study investigated the identification of Candidaspecies isolated from cancer patients using three methods, i.e. germ tube test, colony morphology on chromogenic agar, and API 20 C AUX system, and the antifungal susceptibility of the isolates to fluconazole, voriconazole and amphotericin B. Subsequently, a set of Candida isolates obtained from healthy individuals was identified by the similar methods and studied their antifungal susceptibility. This study showed that C. albicans was the most prominent yeast species in the oral microbiota of cancer patients and healthy individuals, as 48.46% of patient isolates were C. albicans and 31.11% of community isolates were C. albicans. This agrees with the findings of Makinen et al (2018) and Ramla et al (2016), who studied oral Candida colonization of cancer patients [22, 23]. Furthermore, 60.59% of the cancer patients carried Candida species in their oral cavity. High percentages of Candida carriage in the oral cavities of cancer patients face a greater risk of oral candidiasis development, which can be increased with cancer therapy [24]. Comparatively fewer healthy individuals were reported as oral Candida carriers, accounting for 44.71%. An investigation by Al-Hassnawi (2007) on oral Candida colonization among cancer patients in Babylon, Iraq, proved that 96.22% of yeast colonizers in the oral cavity were C. albicans, which agrees with our findings [25]. However, the findings of the current study contradict the findings of the study conducted by Davies et al (2002), as they reported that non-albicans Candida species are the most abundant species among their study group consisting of patients with advanced cancer [26]. When considering the overall Candida colonization in the oral cavity, the shift in oral Candida colonization in cancer patients when compared to healthy individuals tallies with the previous studies conducted by Jain et al (2016) which reported that 70% of cancer patients carried Candidain the oral cavities and a drastically lower proportion which accounted for 20% of the individuals of the control group were found to have oral cavities colonized with Candida [27]. Although oral colonization by Candida species cannot alone be called oral candidiasis, excessive Candida colonization or overgrowth may lead to oral candidiasis. Cancer patients are more vulnerable to opportunistic infections such as candidiasis due to their impaired immunity. Almost half of the cancer patients who participated in this study were at risk of the occurrence of oral candidiasis. Apart from C. albicans being the major cause of oral candidiasis, there are various Candida species responsible for oral candidiasis, such as C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. kefyr, C. dubliniensis, C. guilliermondii, C. inconspicua, C. norvegensis, C. lusitaniae, and C. rugosa [28]. All the Candida species are responsible for similar mucositis, but differences can be seen in the invasiveness, virulence, and antifungal susceptibility patterns among species [29]. Although C. albicans was the predominant oral colonizer among both groups, a considerable number of non-albicans Candida species were isolated from cancer patients and the control group. Interestingly, the number of Candida species isolated from cancer patients was greater than from their counterparts. Eleven Candida species were isolated from cancer patients who participated in the study, while nine species were isolated from the control group, including C. albicans. Among the non-albicans Candida species obtained from the cancer patients, there were C. dubliniensis (2.31%), C. famata (6.15%), C. glabrata (10.77%), C. guilliermondii (2.31%), C. krusei (8.46%), C. parapsilosis (14.62%), C. pelliculosa (1.54%), C. rugosa (0.77%), C. utilis (0.77%), and C. tropicalis (0.77%). The non-albicans Candida species isolated from the community group were C. dubliniensis (11.11%), C. famata (10.00%), C. glabrata (5.56%), C. guilliermondii (5.56%), C. krusei (10.00%),C. parapsilosis (16.67%), C. rugosa (3.33%), and C. tropicalis(2.22%). According to a study carried out by Muadcheingka and Tantivitayakul (2015) using patients with oral candidiasis, C. albicans was the most abundant species, followed by C. glabrata, C. tropicalis, C. parapsilosis, C. kefyr, C. dubliniensis, C. lusitaniae, C. krusei, and C. guilliermondii, which closely align with our findings[30]. In certain circumstances, there is an equal risk for the occurrence of oral candidiasis due to the presence of non-albicans Candida species. The preliminary confirmation of the isolates was done by colony morphology on CCA and Gram staining of the pure cultures, followed by the germ tube test. In this study, CCA was basically used for the selective isolation of Candida species from the oral swab and oral rinse samples that were potentially comprised of numerous microorganisms, as the species-level Candida isolation is based on the bioMérieux API 20 C Aux yeast identification system. Conversely, within the limited number of conventional antifungal agents, azole antifungals are a frequently prescribed class of antifungals for Candida infections. Due to their low toxicity and inexpensive nature, azoles such as fluconazole are often the drug of choice for various Candida infections [31]. The growing use of azole antifungals to treat systemic and mucosal Candida infections has led to the selection and emergence of resistant strains of the disease in patients with potentially fatal disseminated Candida infections. This resistance to azoles could pose a significant clinical issue, especially when there is a severe underlying disease or immunodeficiency [32]. C. krusei is intrinsically resistant to fluconazole, which is a widely used azole antifungal. This inherent resistance is due to the low affinity of C. krusei and its lanosterol 14-α-demethylase enzyme (Erg11p), the target of fluconazole, which prevents effective binding of fluconazole and its inhibition [33]. In the present study, all the C. krusei isolates from both cancer patients and healthy individuals demonstrated resistance to fluconazole, reinforcing the well-documented intrinsic resistance of C. krusei. On the other hand, fluconazole resistance in C. glabrata has become an increasing concern in clinical settings, particularly due to its reduced innate susceptibility to azole antifungals and its ability to rapidly develop resistance during treatment. Unlike C. albicans, C. glabrata lacks the ability to form hyphae but compensates through efficient stress response mechanisms and genomic plasticity [34]. Resistance to fluconazole in this species is frequently linked to the overexpression of ATP-binding cassette (ABC) transporter genes such as CDR1 and CDR2, which facilitate the active efflux of the drug from the cell [35]. Additionally, gain-of-function mutations in the PDR1 transcription factor contribute to the upregulation of these transporters and confer a multidrug-resistant phenotype. Alterations in the ERG11 gene, which encodes the target enzyme of azoles, lanosterol 14α-demethylase, may also contribute to reduced drug binding and therapeutic failure [36]. These resistance mechanisms, combined with an increased prevalence of C. glabrata infections among immunocompromised individuals, pose significant challenges in clinical settings and necessitate the routine use of antifungal susceptibility testing to guide effective treatment strategies. According to the results of our study, both C. albicans and non-albicans Candida species exhibited both azole and amphotericin B resistance. Not only among the cancer patients, antifungal-resistant Candida species were also isolated from the healthy control group, depicting the severity of the antifungal resistance crisis. High percentages of azole resistance and relatively lower percentages of amphotericin B resistance were more or less common in both the test group and the control group. This tendency seriously limits the available treatment options for mycoses caused by C. albicans. Although azole resistance in C. dubliniensis was observed among cancer patients and healthy individuals, all the C. dubliniensis isolates were amphotericin B sensitive. Interestingly, no resistance was reported for C. rugosa in both populations. However, multidrug-resistant C. krusei has become a major clinical concern [37], and azole, echinocandin, and amphotericin B resistance of C. glabrata have been reported [38, 39], confirming the findings of this study. Moreover, C. rugosa has also been identified as an emerging fungal pathogen acquiring azole and amphotericin B resistance [40, 41]. Although reduced susceptibility to azoles and echinocandins has been reported for C. famata [42], amphotericin B resistance has not been reported for C. famata. Surprisingly, amphotericin B-resistant C. famata species were isolated from both groups. When considering C. guilliermondii, C. parapsilosis, and C. tropicalis, azole-resistant isolates were identified, and amphotericin B resistance was not reported among those species. Savini et al (2010) reported a case of azole-resistant C. guilliemondii species isolated from a leukemia patient with silent fungemia that closely aligns with our findings [42]. Our findings regarding C. utilis susceptibility to azoles and amphotericin B agree with the findings reported by Singh et al (2024) [43]. Voriconazole resistance was reported for C. pelliculosa isolated from cancer patients, and a previously published case of isolation of voriconazole-resistant C. pelliculosa from a patient who underwent cardiac surgery by Kcrmery et al (2009) confirms our findings regarding the voriconazole resistance of C. pelliculosa [44]. The tested isolates were more susceptible to amphotericin B than to azoles. In certain circumstances, azole and amphotericin B resistance were common among C. albicans and non-albicans Candida species, which creates the alarming necessity for alternative antifungal agents with different chemical compositions and modes of action. Conclusion The findings of the study emphasize that, in addition to commonly found C. albicans, a wide range of non-albicans Candidaspecies, including C. dubliniensis, C. parapsilosis, C. famata, C. glabrata, C. krusei, C. rugosa, C. pelliculosa, C. guilliermondi, and C. utilis were isolated from the oral cavities of cancer patients. The presence of these non-albicans Candidaspecies is clinically significant as they are recognized as opportunistic fungal pathogens with distinct virulence traits and diverse antifungal resistance patterns. The antifungal susceptibility findings further highlight the emergence of resistance to azole antifungals and, notably, resistance to amphotericin B among the Candida isolates, raising concerns regarding the limited therapeutic options available to treat oral candidiasis in cancer patients who are already at an increased risk for systemic candidiasis due to impaired immunity. The detection of resistant Candidastrains underscores the importance of continuous surveillance of Candida species distribution and antifungal susceptibility profiles in high-risk patient populations such as cancer patients. To sum up, these findings highlight the requirement of routine mycological monitoring in oncology settings and the rational use of conventional antifungal drugs to mitigate the emergence of resistance. Acknowledgements All the participants of the study are gracefully acknowledged. Abbreviations Candida Chrome Agar Colony Forming Units Sabouraud Dextrose Agar Authors’ contributions DW collected clinical samples, conducted laboratory tests, analyzed data, and wrote the original manuscript. SW, GW, and MN conceptualized the research, designed the experiments, supervised the research, and revised the first manuscript. All authors read and approved the final manuscript. Funding This study was funded by the National Science Foundation of Sri Lanka (Grant number: RG/2019/BS/02). Data availability All data generated or analysed during this study are included in this published article. Declarations Ethics approval and consent to participate The study protocol was approved by the Ethics Review Committee of the Faculty of Medicine, University of Ruhuna, Sri Lanka, under ERC Number 2019/P/059 on 27 November 2019. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analysed during this study are included in this published article.